iEuroEwing

The CI for the iEuroEwing trial is Professor Uta Dirksen, University Hospital Essen (Germany).

The trial is international and is open to recruitment.

Main objectives

iEuroEwing-SR part: The main goal is to conduct a randomised trial part. This will examine, whether the addition of a maintenance treatment using VinoCyc to nine cycles of VDC/IE improves EFS in patients with primary disease, aiming at a 10% increase of a 3-year EFS compared to the standard VDC/IE treatment.

iEuroEwing-SR part RT: The main goal is to show in a randomised setting, that a higher RT dose is not inferior regarding an acute skin toxicity CTCAE grade≥3 under RT. The non-inferiority margin for the risk difference is 8% between the combined lower dose and combined higher dose RT arms.

iEuroEwing-HR part: The main goal is to conduct a randomised trial part. This will examine, whether the addition of a maintenance treatment using VinoCyc to nine cycles of VDC/IE improves EFS in patients with primary disseminated
disease, aiming at a 17% increase of 2-year EFS compared to the standard VDC/IE treatment.

More information

More information is available at the EU Clinical Trials Register.